Welcome to our dedicated page for ENDO INTL PLC ORD news (Ticker: $ENDPQ), a resource for investors and traders seeking the latest updates and insights on ENDO INTL PLC ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ENDO INTL PLC ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ENDO INTL PLC ORD's position in the market.
Rhea-AI Summary
Par Pharmaceutical, a subsidiary of Endo International plc, has issued a voluntary recall of seven lots of Treprostinil Injection due to potential silicone particulates in the product solution. The recall is due to the risk of adverse events if the particulate matter reaches the blood vessels, potentially causing serious health issues. Par has not received any reports of adverse events related to the recall. The affected lots were distributed nationwide to wholesalers and hospitals between June 16, 2022, and August 7, 2023. Consumers are advised to contact their healthcare provider if they have experienced any issues related to the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) through its operating company Par Pharmaceutical, Inc., has launched ibuprofen-famotidine tablets, a generic version of Horizon Therapeutics' DUEXIS®, to treat arthritis and reduce stomach ulcer risks. The medication targets a $49 million market and carries warnings about cardiovascular and gastrointestinal risks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40%
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) expects to complete its financial restructuring by late April 2024 after the confirmation of its Chapter 11 plan of reorganization. The company's assets will be sold to a new entity, Endo, Inc., with a significant reduction in outstanding debt and resolution of prior litigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
Rhea-AI Summary
Endo International plc's Par Pharmaceutical, Inc. is recalling a lot of Treprostinil Injection due to potential silicone particulates, with risks of local irritation, swelling, and serious health issues. The recall affects Lot 57014, distributed nationwide from June to October 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) reported a 10% decrease in total revenues for the fourth quarter of 2023 compared to the same period in 2022. The reported loss from continuing operations was $2.44 billion, a significant increase from the previous year. Adjusted income from continuing operations decreased by 20% in the fourth quarter of 2023. The Branded Pharmaceuticals segment saw an increase in revenues, driven by Specialty Products. However, the Sterile Injectables and Generic Pharmaceuticals segments experienced revenue declines. Endo provided financial guidance for 2024 with uncertainties related to competitive assumptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Endo International plc (ENDPQ) resolves DOJ investigations related to Opana® ER marketing, positioning itself for sustained success through financial restructuring and compliance enhancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
Rhea-AI Summary
Endo International plc (ENDPQ) announced the publication of a consensus study in the Journal of Hand Surgery Global Open, indicating that XIAFLEX has a wide-ranging application for the treatment of Dupuytren's contracture. The study findings suggest a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80%
Tags
-
Rhea-AI Summary
Paladin Labs Inc., a subsidiary of Endo International plc, announced the availability of XCOPRI (cenobamate tablets) in Canada for the management of partial-onset seizures in adults with epilepsy. The drug received favorable recommendations for public reimbursement in 2023 and the company is working with government payers to ensure patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.67%
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) announced two new presentations related to Dupuytren's contracture and XIAFLEX® during the American Association for Hand Surgery (AAHS) annual meeting. The research, funded by Endo, aims to improve patient outcomes and presents noteworthy results in the treatment of the proximal interphalangeal (PIP) joint with XIAFLEX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
Rhea-AI Summary
Endo International plc (OTC: ENDPQ) is on track to conclude its financial restructuring process by filing a proposed Plan of Reorganization, paving the way for a strengthened balance sheet and business transformation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.45%
Tags
ENDO INTL PLC ORD
OTC:ENDPQ
ENDPQ Rankings
ENDPQ Stock Data
70.57k
233.69M
0.65%
0.22%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Dublin
About ENDPQ
endo international plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – endo pharmaceuticals, par pharmaceutical, paladin labs, somar and litha. endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from the dupont merck pharmaceutical company. since that time, the company has expanded to include the following business segments: u.s. branded pharmaceuticals, u.s. generic pharmaceuticals and international pharmaceuticals. endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. additionally, we are leveraging